An FDA panel votes 11-0 in favor of the risk/benefit assessment for Onyx Pharmaceuticals' (ONXX)...

|By:, SA News Editor

An FDA panel votes 11-0 in favor of the risk/benefit assessment for Onyx Pharmaceuticals' (ONXX) Kyprolis (carfilzomib) cancer drug for multiple myeloma. ONXX shares have been halted since ~12:30, but Ligand Pharma (LGND), which is due to receive milestone payments and royalties for the drug, rose 12.8% during regular trading and is +3.8% AH.